Astrana Health Inc.
ASTH Small CapHealthcare · Medical Care Facilities
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Astrana Health Inc. en bref
Astrana Health Inc. (ASTH) is currently trading at 34,15 € with a market capitalization of 1,7 Md €. The trailing P/E ratio stands at 64.21x, with a forward P/E of 11.49x. The 52-week range spans from 15,76 € to 34,98 €; the current price is 2.4% below the yearly high. Year-over-year revenue growth stands at +55.6%. The net profit margin stands at 0.86%.
💰 Dividende
Astrana Health Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
9 analystes évaluent Astrana Health Inc. (ASTH) au consensus : Achat Fort. L'objectif de cours moyen est de 40,10 €, soit un potentiel de +17.44% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 35,74 € à 43,59 €.
Astrana Health Inc. : la thèse d'investissement en détail
Astrana Health Inc. (ASTH) operates in the Healthcare — specifically Medical Care Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 55.6% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. Wall Street consensus sits at Strong Buy with an average price target implying roughly 17.44% upside from current levels — analyst sentiment is firmly constructive.
Le scénario baissier
With a net margin of just 0.86%, the business has little room to absorb cost shocks or pricing pressure — a single bad quarter can swing the company to a loss. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
À surveiller
- The forward P/E of 11.49x is meaningfully below the trailing 64.21x — analysts expect earnings to step up; the next earnings release is the test.
- The share is trading at 95.6% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 55.6% sur un an
- Consensus des analystes : Strong Buy
- Free cash flow positif
- –Faible rentabilité (marge 0.86%)
- –Multiple de valorisation élevé (P/E 64.21x)
- –Actuellement jugée surévaluée
- –Endettement élevé (D/E 184.46)
- –Cours proche du plus haut 52 semaines — faible marge de hausse
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (9.22%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Astrana Health Inc.?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news